» Articles » PMID: 10794849

Midlife Blood Pressure and Neuritic Plaques, Neurofibrillary Tangles, and Brain Weight at Death: the HAAS. Honolulu-Asia Aging Study

Overview
Journal Neurobiol Aging
Publisher Elsevier
Date 2000 May 5
PMID 10794849
Citations 184
Authors
Affiliations
Soon will be listed here.
Abstract

Midlife hypertension is associated with later development of cognitive impairment, vascular dementia (VsD), and possibly Alzheimer's disease (AD). Neuropathic cerebrovascular lesions and brain atrophy have been associated with elevated blood pressure (BP), however, to our knowledge there have been no prospective investigations of an association of blood pressure levels measured in midlife with the microscopic lesions of AD. We investigated the relationship of BP level in midlife to development of neurofibrillary tangles (NFT), neuritic plaques (NP), and low brain weight at autopsy among Japanese-American men who were members of the Honolulu Heart Program/Honolulu-Asia aging Study (HHP/HAAS) cohort. The HHP/HAAS is a population-based, longitudinal study of cognitive function and dementia with 36 years of follow-up. Neocortical and hippocampal NFT and NP were counted per mm(2), and fixed brain weight was measured for 243 decedents. Elevated systolic BP, (> or =160 mm Hg) in midlife was associated with low brain weight and greater numbers of NP in both neocortex and hippocampus. Diastolic BP elevation, (> or =95 mm Hg) was associated with greater numbers of NFT in hippocampus. Results indicate that in addition to the accepted association of high BP with neuropathic cerebrovascular lesions, there is a direct relationship with brain atrophy, NP and NFT.

Citing Articles

Effect Modifiers of the Association of Blood Pressure With Brain Amyloid and Tau Pathology.

Cai W, Neitzel J, Glodzik L, Blacker D, Ma Y Neurology. 2025; 104(6):e213441.

PMID: 40014836 PMC: 11874733. DOI: 10.1212/WNL.0000000000213441.


Effects of strategic white matter hyperintensities of cholinergic pathways on basal forebrain volume in patients with amyloid-negative neurocognitive disorders.

Kim Y, Lim J, Suh C, Heo H, Roh J, Cheong E Alzheimers Res Ther. 2024; 16(1):185.

PMID: 39148136 PMC: 11325579. DOI: 10.1186/s13195-024-01536-2.


Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation.

Oliai S, Shippy D, Ulland T J Neuroimmunol. 2024; 391:578364.

PMID: 38718558 PMC: 11165694. DOI: 10.1016/j.jneuroim.2024.578364.


Association between Incidence of Prescriptions for Alzheimer's Disease and Beta-Adrenoceptor Antagonists: A Prescription Sequence Symmetry Analysis.

Alghamdi A, Bijlsma M, de Vos S, Schuiling-Veninga C, Bos J, Hak E Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139820 PMC: 10748070. DOI: 10.3390/ph16121694.


The relationship of small vessel disease burden on cerebral and regional brain atrophy rates and cognitive performance over one year of follow-up after transient ischemic attack.

Reaume N, Reid M, Tadros G, Chacinski D, Denroche B, Aftab A Front Neurol. 2023; 14:1277765.

PMID: 38073643 PMC: 10704595. DOI: 10.3389/fneur.2023.1277765.